Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
Clinical trial NCT05095636 · UNKNOWN
Trial details
- NCT number
- NCT05095636
- Sponsor
- Fudan University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-17
- Primary completion
- 2023-03-01
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.